Onchocerciasis Control and Epidemiology

Onchocerciasis, commonly known as river blindness, is a parasitic disease caused by Onchocerca volvulus and transmitted by Simulium blackflies. It remains endemic in parts of sub-Saharan Africa, Latin America and Yemen. Control efforts since the 1980s have centred on mass drug administration (MDA) of ivermectin, which reduces microfilarial loads in human hosts and interrupts transmission by blackflies. Over decades, community-directed treatment with ivermectin has transformed hyperendemic foci into areas approaching elimination thresholds. Concurrent challenges include co‐endemic Loa loa infections that elevate the risk of severe adverse reactions, the potential emergence of drug resistance, and the optimisation of treatment regimens—annual versus biannual or alternative drugs such as moxidectin. Epidemiological models have guided policy by predicting timeframes for elimination under different coverage and frequency scenarios. Recent attention has also focused on onchocerciasis‐associated morbidities, including forms of epilepsy, and on refining strategies to reach underserved or high‐risk populations. The global significance lies not only in alleviating a leading cause of preventable blindness and disability, but also in demonstrating how large-scale MDA and adaptive strategies can drive neglect­ed tropical disease programmes towards elimination.

Research from Nature Portfolio

Recent studies have integrated the risk of onchocerciasis-associated epilepsy into transmission models to quantify the broader health impact of MDA. Using an individual-based stochastic model, researchers simulated 19 years of ivermectin distribution in hyper- and holoendemic settings with realistic coverage levels. Scenario analyses comparing annual and biannual MDA revealed that biannual treatment with 80% coverage could eliminate onchocerciasis-associated epilepsy and protect untreated young children in highly endemic areas within 25 years. These findings underscore the importance of adaptive strategies, early treatment of under-fives and the strengthening of programmes in persistent transmission zones.

Onchocerciasis Control and Epidemiology publication trend

The graph below shows the total number of articles in onchocerciasis control and epidemiology across all publications each year (not limited to Nature Index journals).

Technical terms

Microfilariae: Larval stage of Onchocerca volvulus present in the skin, responsible for pathology and transmission.

Mass drug administration (MDA): Scheduled distribution of antiparasitic medication to entire at-risk communities, irrespective of individual infection status.

Hyperendemic: Describes areas with very high disease prevalence, typically requiring intensified intervention efforts.

EPIONCHO-IBM: An individual-based, stochastic transmission model used to simulate the impact of onchocerciasis control strategies over time.

Loiasis: Infection by the filarial parasite Loa loa, which can complicate ivermectin treatment by causing severe adverse events in heavily infected individuals.

References

1. Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results. Infectious Diseases of Poverty (2016).
2. Phenotypic Evidence of Emerging Ivermectin Resistance in Onchocerca volvulus. PLOS Neglected Tropical Diseases (2011).
3. A Test-and-Not-Treat Strategy for Onchocerciasis in Loa loa–Endemic Areas. New England Journal of Medicine (2017).
4. Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis. Parasites & Vectors (2015).
5. Modelling onchocerciasis-associated epilepsy and the impact of ivermectin treatment on its prevalence and incidence. Nature Communications (2024).
6. Association between blood Loa loa microfilarial density and proteinuria levels in a rural area of the Republic of Congo (the MorLo project): a population-based cross-sectional study. The Lancet Microbe (2023).
7. An Updated Economic Assessment of Moxidectin Treatment Strategies for Onchocerciasis Elimination. Clinical Infectious Diseases (2024).